Alveolus Bio is focused on developing innovative biotherapeutics aimed at preventing and treating chronic lung diseases. Their proprietary resMIT platform is designed to deliver targeted bacteria directly to the lungs, specifically addressing conditions such as Idiopathic Pulmonary Fibrosis (IPF) and neutrophilic inflammation associated with diseases like Chronic Obstructive Pulmonary Disease (COPD) and Non-Cystic Fibrosis Bronchiectasis (NCFBE). This targeted delivery system aims to disrupt the current standard of care by effectively addressing fibroblast dysfunction and inflammation in the lungs.

The company is comprised of a multidisciplinary team of scientists, clinicians, and engineers dedicated to revolutionizing the treatment landscape for chronic respiratory diseases. By leveraging their advanced therapeutic platform, Alveolus Bio seeks to provide safe and effective treatment options that can significantly improve patient outcomes in the management of chronic lung conditions. Their commitment to innovation and scientific excellence positions them at the forefront of biotherapeutic development in the respiratory health sector.

United States

Alveolus Bio is a team of scientists, physicians, and innovators pioneering breakthrough FDA-approved therapeutics for lung diseases. Our pipeline includes preclinical stage live biotherapeutics for Idiopathic Pulmonary Fibrosis (IPF), Chronic Obstructive Pulmonary Disease (COPD), and Non-Cystic Fibrosis Bronchiectasis (NCFBE). Inhaled delivery effectively targets the distal regions of the lungs, bypassing first-pass metabolism and enhancing efficacy while reducing adverse effects, differentiating our drugs from other treatments.

Alveolus Bio

Company Details